Company Profile

TxCell is a biotechnology company which develops platforms for innovative customized cell immunotherapies from regulatory T cells (Treg) for the treatment of severe chronic inflammatory, autoimmune diseases and transplant rejection. TxCell is developing a platform for genetically modified T-cells, the CAR-Tregs. TxCell plans to release preclinical proof-of-concept data in 2017 and start a first clinical study by the end of 2018.

Employees

Sector

Biotechnology & Medical Research

More about the company

Real-time Euronext Paris			5-day change	1st Jan Change
- ^EUR	-.--%		-.--%	+67.53%

18-10-01	TxCell : Sangamo and TxCell announce the completion of the acquisition by Sangamo of majority of TxCell ordinary shares	PR
18-07-23	TxCell : Sangamo Therapeutics to Acquire TxCell	PR
18-07-09	TxCell : exercises in-license option to the University of British Columbia’s intellectual property rights of the HLA-A2 CAR-Treg program	PU
18-06-21	TxCell : First in vivo proof-of-concept data with CD8+ CAR-Treg presented at FOCIS 2018	PU
18-05-28	TxCell : to present its latest manufacturing process achievements at the 3rd Annual Bioprocessing of Advanced Cellular Therapies Congress	PU

18-12-03	TxCell : acquisition par Sangamo finalisée
18-11-27	TxCell : retrait obligatoire ce jeudi
18-11-26	TxCell : près de sept millions d'actions apportées à l'OPAS
18-11-23	TXCell : Sangamo Therapeutics dépasse les 90%
18-11-15	TxCell : 'la rencontre avec Sangamo était une évidence'

Manager	Title	Age	Since
Sandrine Boulet COO	Chief Operating Officer	50	-
Pierre Desreumaux PRN	Corporate Officer/Principal	-	-
Bernard Malissen PRN	Corporate Officer/Principal	-	-

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
TXCELL	-.--%	-.--%	-	-	0
WUXI APPTEC CO., LTD.	+0.88%	+1.18%	+40.64%	+74.91%	64.69B
ARGENX SE	-0.26%	+6.91%	+9.79%	+77.36%	54.78B
LONZA GROUP AG	+0.47%	+3.52%	+9.71%	+100.95%	53.49B
IQVIA HOLDINGS INC.	-1.63%	+3.44%	+26.48%	+49.12%	45.98B
BEONE MEDICINES AG	-1.58%	+0.16%	+17.54%	+123.55%	42.94B
REVOLUTION MEDICINES, INC.	-1.01%	+1.05%	+217.40%	+824.46%	40.08B
CELLTRION, INC.	-2.26%	-2.06%	+15.38%	+45.14%	33.52B
WUXI BIOLOGICS (CAYMAN) INC.	+0.22%	-4.77%	+26.59%	+0.55%	23.97B
GENMAB A/S	+12.10%	+16.60%	+58.50%	+46.15%	23.67B
Average	+0.70%	+2.22%	+46.89%	+149.13%	42.57B
Weighted average by Cap.	+0.27%	+2.59%	+44.13%	+150.63%

TxCell Stock

Stocks

TXCL

FR0010127662

Biotechnology & Medical Research

Press Releases: TxCell

News in other languages: TxCell

Managers and Directors: TxCell

Bio Therapeutic Drugs

Company Profile